ClinicalTrials.gg
RecruitingNCT07506122Updated May 14, 2026

Dose-Effect Response in Acupuncture for Functional Constipation

An interventional study of Manual Acupuncture and Electroacupuncture in Functional Constipation (FC), sponsored by Tongji Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Tongji Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.

Planned enrollment
61st of 93
72 · median 100
Started
2026
with 10 others
No phase
56 of 109
21 open now
Primary completion
2027-09
later than 29 of 36 live
Registered
101st of 109
by date

Among the 109 studies in Constipation with a site in China, this one is the 61st largest by planned enrollment of the 93 interventional ones that give a count, is one of 11 that started in 2026, is one of 56 with no phase, reaches primary completion later than 29 of the 36 other live ones, and was the 101st registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Constipation with a site in China, or all of them as a file.
02

Study summary

This is a single-center, randomized, parallel-group trial evaluating the dose-response relationship of two experimental interventions: manual acupuncture and electroacupuncture for functional constipation.

A total of 72 participants with functional constipation (Rome IV criteria) will be randomly assigned in a 1:1 ratio to either the manual acupuncture group or the electroacupuncture group. Both groups receive acupuncture at bilateral Tianshu (ST25) and Shangjuxu (ST37) points, 30 minutes per session, three times per week for 12 weeks. The electroacupuncture group additionally receives electrical stimulation (continuous wave, 10 Hz, 0.5-4 mA).

The primary outcome is the responder rate at week 12, defined as the percentage of participants with ≥3 complete spontaneous bowel movements (CSBMs) per week. Secondary outcomes include changes in gut microbiota, brain functional connectivity measured by multimodal MRI and fNIRS, and scales.

The study aims to clarify the dose-response characteristics of different acupuncture modalities and their underlying biological mechanisms.

03

Conditions studied

  • Functional Constipation (FC)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet Rome IV diagnostic criteria for functional constipation
  • Symptoms present for ≥6 months, meeting diagnostic criteria in the last 3 months
  • Mean weekly complete spontaneous bowel movements (CSBMs) ≤2 during 14-day baseline period
  • Age 18-75 years
  • No use of constipation medications for at least 2 weeks prior to treatment (except rescue medication)
  • No acupuncture treatment for constipation in the past 3 months
  • Not currently participating in another clinical trial
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Constipation secondary to other causes (IBS, organic diseases, medications, endocrine disorders, metabolic disorders, neurological disorders, or gastrointestinal surgery)
  • Loose or watery stools (Bristol type 6 or 7) >1 time during baseline without laxative use
  • History of pelvic floor dysfunction
  • Use of probiotics, fiber supplements, or laxatives within 2 weeks prior to treatment (2-week washout required)
  • Severe hemorrhoids or anal fissures
  • Severe or uncontrolled heart, liver, or kidney disease; abdominal aortic aneurysm; hepatosplenomegaly; cognitive impairment; or psychiatric disorders
  • Dependence on opioids or anticholinergic drugs
  • Red flags: unexplained weight loss >10% in 3 months, hematochezia or positive fecal occult blood, family history of colon cancer (first-degree relative diagnosed \<50 years), anemia ( \<110 g/L), or elevated inflammatory markers
  • to acupuncture: coagulation disorders or use of anticoagulants
  • Pregnancy or breastfeeding
  • Unable to comply with follow-up or contraindications to MRI (e.g., cardiac pacemaker, non-titanium aneurysm clips, metallic implants, claustrophobia)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Manual Acupuncture Group

    Other: Manual Acupuncture

  • Experimental
    Electroacupuncture Group

    Device: Electroacupuncture

Interventions

  • OtherManual Acupuncture

    Acupuncture at bilateral Tianshu (ST25) and Shangjuxu (ST37). Participant lies supine and rests for 5 minutes before treatment. After routine disinfection, the acupuncturist inserts needles vertically to a certain depth, followed by mild lifting, thrusting, and twisting for 10 seconds at each acupoint to induce deqi. Needles are retained for 30 minutes. After removal, needle holes are pressed to prevent bleeding. Treatment frequency: three sessions per week for 12 weeks.

  • DeviceElectroacupuncture

    Acupuncture at bilateral Tianshu (ST25) and Shangjuxu (ST37). Participant lies supine and rests for 5 minutes before treatment. After routine disinfection, the acupuncturist inserts needles vertically to a certain depth, followed by mild lifting, thrusting, and twisting for 10 seconds at each acupoint to induce deqi. Then needles are connected to an electroacupuncture device (Hwato SDZ-III, Suzhou Medical Products Factory, China). Two pairs of electrodes are attached: one pair to bilateral Tianshu (ST25), the other to bilateral Shangjuxu (ST37). Electrical stimulation: continuous wave, 10 Hz, current intensity 0.5-4 mA adjusted to patient tolerance. Electroacupuncture duration: 30 minutes. After needle removal, press to prevent bleeding. Treatment frequency: three sessions per week for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Responder Rate at Week 12

    Percentage of participants with ≥3 complete spontaneous bowel movements (CSBMs) per week at week 12

    Time frame: Week 12

Secondary outcomes

  1. Responder Rate at Week 16

    Percentage of participants with ≥3 complete spontaneous bowel movements (CSBMs) per week at week 16

    Time frame: Week 16

  2. Changes in Blood Flow Measured by DCS

    Changes in blood flow at acupoints, intestinal body surface projection areas, and abdominal muscle tissue measured by diffuse correlation spectroscopy (DCS), with concurrent monitoring of local pressure and temperature

    Time frame: Baseline, after deqi, weeks 2, 4, 6, 8, 10, 12, 16

  3. Changes in Gut Microbiota

    Changes in gut microbiota diversity and composition analyzed by 16S rRNA sequencing, and changes in gut metabolites (e.g., short-chain fatty acids) measured by targeted metabolomics

    Time frame: Baseline, week 12, week 16, and at the time when CSBMs ≥3 per week is achieved

  4. Changes in Brain Function

    Changes in central neural network connectivity, functional activity of core brain regions, and brain glymphatic system function assessed by multimodal MRI

    Time frame: Baseline, after deqi, week 12, week 16, and at the time when CSBMs ≥3 per week is achieved

  5. Changes in Cortical Activity Measured by fNIRS

    Changes in cortical activity assessed by functional near-infrared spectroscopy (fNIRS)

    Time frame: Baseline, after deqi, weeks 2, 4, 6, 8, 10, 12, 16

  6. Acupuncture Expectancy Scale

    A 4-item patient-reported questionnaire assessing patients' expectancy of positive outcomes from acupuncture therapy, including improvement of illness, enhanced coping, increased vitality, and symptom alleviation. Each item is scored from 1 (not at all agree) to 5 (completely agree), with total scores ranging from 4 to 20. Higher scores indicate greater expectancy of benefit from acupuncture treatment.

    Time frame: Baseline

  7. Patient Assessment of Constipation Quality of Life

    A 28-item patient-reported questionnaire assessing constipation-related quality of life, consisting of four domains: physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction. Each item is scored from 0 to 4, with total scores ranging from 0 to 112. Higher scores indicate worse constipation-related quality of life.

    Time frame: Baseline, weeks 2, 4, 6, 8, 10, 12, 16

  8. Generalized Anxiety Disorder 7-item Scale

    A 7-item patient-reported questionnaire assessing anxiety symptoms over the past two weeks. Each item is scored from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 21. Higher scores indicate more severe anxiety symptoms.

    Time frame: Baseline, weeks 2, 4, 6, 8, 10, 12, 16

  9. Patient Health Questionnaire-9

    A 9-item patient-reported questionnaire assessing depressive symptoms over the past two weeks, based on the DSM-IV diagnostic criteria for depression. Each item is scored from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 27. Higher scores indicate more severe depressive symptoms.

    Time frame: Baseline, weeks 2, 4, 6, 8, 10, 12, 16

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 16 months is close to that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 1, 2026
StartActual
May 11, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07506122
Lead sponsor
Tongji Hospital
Responsible party
Xu Shabei (Chief Physician;Associate Professor;Associate Director, Department of Neurology;Associate Director of Clinical Research Center, Tongji Hospital) — Principal investigator
First posted
Apr 1, 2026
Start date
May 11, 2026
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 14, 2026

Study contacts

Wensheng Qu
Contact
Qws0309@163.com
+86-18971622660
Shabei Xu
Contact
xushabei@126.com
+86-13554178768
Shabei Xu
principal investigator · Tongji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion